vs
ACCO BRANDS Corp（ACCO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是ACCO BRANDS Corp的1.5倍（$622.0M vs $428.8M），Royalty Pharma plc净利率更高（34.4% vs 5.0%，领先29.5%），Royalty Pharma plc同比增速更快（4.8% vs -4.3%），过去两年ACCO BRANDS Corp的营收复合增速更高（9.3% vs 4.6%）
ACCO Brands是一家美国跨国企业，由财富品牌旗下的ACCO World与通用装订公司GBC合并组建而成，截至2025年，公司董事长兼首席执行官为Thomas W. Tedford，主营办公文具与办公用品相关业务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ACCO vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.5倍
$428.8M
营收增速更快
RPRX
高出9.1%
-4.3%
净利率更高
RPRX
高出29.5%
5.0%
两年增速更快
ACCO
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $428.8M | $622.0M |
| 净利润 | $21.3M | $214.2M |
| 毛利率 | 33.6% | — |
| 营业利润率 | 9.3% | 62.4% |
| 净利率 | 5.0% | 34.4% |
| 营收同比 | -4.3% | 4.8% |
| 净利润同比 | 3.4% | 2.9% |
| 每股收益（稀释后） | $0.23 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACCORPRX
| Q4 25 | $428.8M | $622.0M | ||
| Q3 25 | $383.7M | $609.3M | ||
| Q2 25 | $394.8M | $578.7M | ||
| Q1 25 | $317.4M | $568.2M | ||
| Q4 24 | $448.1M | $593.6M | ||
| Q3 24 | $420.9M | $564.7M | ||
| Q2 24 | $438.3M | $537.3M | ||
| Q1 24 | $358.9M | $568.0M |
净利润ACCORPRX
| Q4 25 | $21.3M | $214.2M | ||
| Q3 25 | $4.0M | $288.2M | ||
| Q2 25 | $29.2M | $30.2M | ||
| Q1 25 | $-13.2M | $238.3M | ||
| Q4 24 | $20.6M | $208.2M | ||
| Q3 24 | $9.3M | $544.0M | ||
| Q2 24 | $-125.2M | $102.0M | ||
| Q1 24 | $-6.3M | $4.8M |
毛利率ACCORPRX
| Q4 25 | 33.6% | — | ||
| Q3 25 | 33.0% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 31.4% | — | ||
| Q4 24 | 34.7% | — | ||
| Q3 24 | 32.5% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 30.8% | — |
营业利润率ACCORPRX
| Q4 25 | 9.3% | 62.4% | ||
| Q3 25 | 6.8% | 70.1% | ||
| Q2 25 | 8.4% | 36.3% | ||
| Q1 25 | -2.1% | 94.0% | ||
| Q4 24 | 9.4% | 60.9% | ||
| Q3 24 | 6.2% | — | ||
| Q2 24 | -25.4% | 50.2% | ||
| Q1 24 | 1.6% | -13.0% |
净利率ACCORPRX
| Q4 25 | 5.0% | 34.4% | ||
| Q3 25 | 1.0% | 47.3% | ||
| Q2 25 | 7.4% | 5.2% | ||
| Q1 25 | -4.2% | 41.9% | ||
| Q4 24 | 4.6% | 35.1% | ||
| Q3 24 | 2.2% | 96.3% | ||
| Q2 24 | -28.6% | 19.0% | ||
| Q1 24 | -1.8% | 0.8% |
每股收益（稀释后）ACCORPRX
| Q4 25 | $0.23 | $0.49 | ||
| Q3 25 | $0.04 | $0.67 | ||
| Q2 25 | $0.31 | $0.07 | ||
| Q1 25 | $-0.14 | $0.55 | ||
| Q4 24 | $0.21 | $0.46 | ||
| Q3 24 | $0.09 | $1.21 | ||
| Q2 24 | $-1.29 | $0.23 | ||
| Q1 24 | $-0.07 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $664.6M | $9.7B |
| 总资产 | $2.3B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ACCORPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务ACCORPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益ACCORPRX
| Q4 25 | $664.6M | $9.7B | ||
| Q3 25 | $644.0M | $9.6B | ||
| Q2 25 | $637.3M | $9.5B | ||
| Q1 25 | $606.1M | $9.8B | ||
| Q4 24 | $606.1M | $10.3B | ||
| Q3 24 | $615.5M | $10.3B | ||
| Q2 24 | $617.1M | $9.8B | ||
| Q1 24 | $758.5M | $9.9B |
总资产ACCORPRX
| Q4 25 | $2.3B | $19.6B | ||
| Q3 25 | $2.3B | $19.3B | ||
| Q2 25 | $2.4B | $18.3B | ||
| Q1 25 | $2.3B | $17.6B | ||
| Q4 24 | $2.2B | $18.2B | ||
| Q3 24 | $2.4B | $18.0B | ||
| Q2 24 | $2.4B | $17.7B | ||
| Q1 24 | $2.5B | $16.1B |
负债/权益比ACCORPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.6M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.44× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACCORPRX
| Q4 25 | $30.6M | $827.1M | ||
| Q3 25 | $71.5M | $702.6M | ||
| Q2 25 | $-38.9M | $364.0M | ||
| Q1 25 | $5.5M | $596.1M | ||
| Q4 24 | $52.7M | $742.5M | ||
| Q3 24 | $92.9M | $703.6M | ||
| Q2 24 | $-25.6M | $658.2M | ||
| Q1 24 | $28.2M | $664.6M |
现金转化率ACCORPRX
| Q4 25 | 1.44× | 3.86× | ||
| Q3 25 | 17.88× | 2.44× | ||
| Q2 25 | -1.33× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.56× | 3.57× | ||
| Q3 24 | 9.99× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACCO
| Transferred At Point In Time | $421.6M | 98% |
| Transferred Over Time | $7.2M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
